MUSC Hollings Cancer Center
Medical University of South Carolina
Charleston, SC
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
- Monoclonal Antibody
- Phase 1
Accepting patients
ASTX030
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Learn more- DNMT1 Inhibitor
- Phase 2/3
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Learn more- Monoclonal Antibody
- CD47
- Closed Label (Masked)
- Placebo
- Randomization
- Phase 2